Follow us

About us

Founded in 2015 by two scientists, Géraldine Le Duc (CEO of NH TherAguix) and Pr Olivier Tillement (scientific advisor of NH TherAguix, Professor of Chemistry at University of Lyon), NH TherAguix is a French biotechnology company based in Grenoble. NH TherAguix has developed an innovative theranostic nanodrug called AGuIX® that allows to fight more efficiently against all forms of cancer. 
Thanks to a €13M fund raising in 20219 (BPI, Innobio, Omnes, Arbevel, Supernova), NH THerAguix was able to launch a promising portfolio of clinical trials.

Management

Géraldine Leduc

Géraldine Le Duc, PhD

Chief Executive Officer & Co-Founder

  • 30 years of expertise in drugs for radiotherapy and imaging of cancer (Guerbet, INSERM, BNL-USA, ESRF)
  • More than 100 scientific publications, 4 patents
  • Discovery of the radiosensitization effect of AGuIX®
  • PhD in Biomedical Physics
CONTRAST-AGENT2

Markus Loeffler, MD & MBA

Chief Medical Officer

  • More than 20 years of international leadership experience in oncology (Boehringer Ingelheim, Roche, AAA, Mundipharma EDO)
  • Expertise in all stages of research and clinical development from first in human to market
  • MD & MBA from INSEAD
Michel Julien

Michel Julien, PhD

CMC Director

  • Over 20 years of experience in parenteral drug research and development
  • Strong expertise in CMC activities from lead candidate selection to manufacturing process validation including management of CMOs
  • PhD in Biochemistry
caroline-cayre

Caroline Cayre

Head of Finance and Administration

  • 25+ years spent in Finance & Business administration, including 15 years in international business environment
  • Broad industry experience: Audit (PwC), Large international groups (HP), Fast growing SMEs/Start-ups (Aledia)
  • French Business School (1995) – Studies abroad (Bath-UK), Certified Coach (Teams & Organizations)

Board of directors

Géraldine Leduc

Géraldine Le Duc

CEO & Co-Founder

herve-brailly

Hervé Brailly

Chairman

olivier-tillement

Olivier Tillement

Scientific Advisor & Co-Founder
AGuIX® Inventor, University Professor

philippe-boucheron

Philippe Boucheron

Life Sciences Investor
Bpifrance

thibaut-roulon

Thibaut Roulon

Life Sciences Investor
Bpifrance

herve-brailly

Nitza Thomasson

Life Sciences Investor
Omnes

marc-lebozec

Marc Lebozec

Life Sciences Investor
Arbevel

marc-lebozec

Célia Hart

Life Sciences Investor
Supernova

yannick-pletan

Yannick Pletan

Formely Country Medical Director
Roche

philippe-archinard

Philippe Archinard

Deputy CEO-Innovation & Scientific Partnerships
Institut Mérieux

Partners

BPI France
Arbevel
Omnes
Supernova
Pulsayis
Université Claude Bernard Lyon 1
Région Auvergne Rhône-Alpes